Skip to content
Calculator
Evidence: MediumPeptideIn Clinical TrialsAntiarrhythmic dipeptideInvestigational · phase 2 negative in heart attackDiabetic retinopathy

Danegaptide

A connexin-43 gap junction modifier, from heart attack to diabetic eye disease

Danegaptide (ZP1609) is an oral dipeptide analogue of rotigaptide that modifies connexin-43, the protein that forms gap junctions linking neighbouring cells. It reduced infarct size in pigs, but a 585-patient phase 2 trial in heart attack found no benefit. It has since been tested in diabetic retinopathy, where a 24-patient phase 1b study in 2026 found no serious drug-related adverse events.

No established human dose Details ↓

Overview

What is it?

Gap junctions are channels built from connexin proteins that let neighbouring cells share ions and small molecules. In the heart, connexin-43 keeps muscle cells electrically coupled; in the brain it links astrocytes; and half-channels, or hemichannels, can leak ATP from injured cells. Danegaptide was developed as a small, orally available relative of rotigaptide, an antiarrhythmic peptide targeting connexin-43.

The animal results were encouraging. Given ten minutes before reperfusion in pigs after an hour of coronary occlusion, it cut infarct size from 46% to 25% of the area at risk, as much as ischaemic postconditioning. In mice it crossed the blood-brain barrier, increased astrocyte coupling and reduced infarct volume after stroke. In human kidney cells it blocked hemichannel ATP release and protected against TGF-beta1 injury. But in pigs with kidney ischaemia it did not improve kidney function at two weeks.

The heart attack trial gave the clearest answer. Patients with STEMI undergoing primary angioplasty were randomised to high-dose or low-dose danegaptide or placebo; 585 were enrolled and about 80 per group had evaluable cardiac MRI at three months. Myocardial salvage, final infarct size and ejection fraction did not differ, nor did clinical outcomes.

In 2026 a Dublin group reported that danegaptide improved the blood-retina barrier in animal models and countered VEGF-driven leakage in human retinal cells, partly through the protein TNFSF15. In an early phase 1b trial of oral danegaptide in 24 patients with nonproliferative diabetic retinopathy and mild macular oedema, there were no serious drug-related adverse events. Whether it helps vision is untested.

585
Patients in the STEMI phase 2 trial
no gain in myocardial salvage · PMID 29602883
24
Patients in the retinopathy phase 1b
oral, no related serious events · PMID 42777083
25% vs 46%
Infarct size in pigs
of the area at risk, against control · PMID 23397587
Science

Mechanism of Action

Danegaptide is a small dipeptide gap-junction modifier, designed from rotigaptide, that keeps connexin-43 channels between cells open under stress.

❤️

Heart muscle under ischaemia

In pigs and dogs it shrank infarcts and made arrhythmias and atrial fibrillation harder to induce, but in 585 people treated for STEMI it did not increase myocardial salvage.

👁️

Retinal barrier

In retinal cells and animal models it tightened the inner blood-retina barrier through connexin-43 and by countering VEGF, and an oral form passed a 24-patient safety trial.

🧠

Astrocyte coupling

After stroke in mice and rats it increased connexin-43 coupling between astrocytes and enhanced synaptic plasticity.

Evidence

Published Research

These studies were read from their PubMed abstracts: the phase 2 trial in heart attack patients that missed its endpoint, the phase 1 and preclinical work in diabetic retinopathy, the discovery chemistry, and animal studies in heart, kidney and brain ischaemia. The literature is mostly preclinical, and the one large clinical trial was negative.

Human2018

Phase 2 in STEMI

Of 585 patients randomised to two dose levels of danegaptide or placebo alongside primary PCI for STEMI, 243 met the imaging criteria for per-protocol analysis; at three months cardiac MRI showed no difference in myocardial salvage index (63.9, 65.6 and 66.7 for high dose, low dose and placebo), final infarct size or ejection fraction, and clinical outcomes did not differ. Zealand Pharma staff were among the authors.

PMID: 29602883
Human2026

Diabetic retinopathy: preclinical and phase 1b

In human retinal microvascular cells and animal models, danegaptide improved inner blood-retina barrier function through connexin-43 and by acting as a functional antagonist of VEGF; in a phase 1b trial in 24 patients with non-proliferative diabetic retinopathy and mild centre-involved macular oedema, oral danegaptide caused no serious adverse events attributed to it. Authors from Breye Therapeutics, which is developing it, took part.

PMID: 42777083
Animal2013

Infarct size in pigs

Given 10 minutes before reperfusion after 60 minutes of coronary occlusion, ZP1609 reduced infarct size to 25% of the area at risk versus 46% with immediate reperfusion, similar to ischaemic postconditioning (31%).

PMID: 23397587
Animal2020

Stroke in mice

Danegaptide increased astrocytic connexin-43 coupling without affecting hemichannels, reached brain tissue within an hour of reperfusion, and significantly reduced infarct volume.

PMID: 32110860
Animal2016

Kidney ischaemia in pigs

In 20 pigs with unilateral renal ischaemia-reperfusion, danegaptide infusion did not change GFR immediately or at 14 days, urinary NGAL or renal blood flow.

PMID: 27760220
In Vitro2021

Human kidney tubule cells

Danegaptide blocked connexin-43 hemichannel ATP release in primary human proximal tubule cells, reduced paracellular permeability and inhibited TGF-beta1-induced cytokine changes.

PMID: 33802083
Animal2009

Arrhythmias and infarct size

In open-chest dogs given 60 minutes of coronary ischaemia, GAP-134 started 10 minutes before reperfusion prevented spontaneous ventricular arrhythmias and cut infarct size from 19.0% of the left ventricle in controls to 7.9% and 7.1% at its two highest doses, which the authors read as antiarrhythmic action with the potential to limit ischaemia-reperfusion injury. Wyeth researchers ran the study.

PMID: 19721133
Animal2009

Atrial fibrillation in a dog model

In the canine sterile pericarditis model, GAP-134 consistently improved conduction and reduced how easily atrial fibrillation and flutter could be induced; with its oral absorption, the authors treat this as support for its antiarrhythmic potential.

PMID: 19252062
Animal2009

Long-term dosing in dogs: a qualified result

Oral GAP-134 given chronically reduced the pacing-induced fall in left atrial wavelength and appeared to lessen vulnerability to atrial fibrillation in dogs with less atrial mechanical remodelling, leading the authors to conclude that gap junction modulation affects atrial fibrillation only in some circumstances.

PMID: 19808462
In Vitro2009

How the molecule was found

The dipeptide now called danegaptide was selected from compounds designed on a pharmacophore model of rotigaptide and confirmed in a mouse cardiac conduction block model, as a potent gap-junction modifier that works by mouth and could be developed clinically.

PMID: 19175320
In Vitro2017

Protecting heart cells, but not through mitochondria

ZP1609 reduced the proportion of heart muscle cells undergoing hypercontracture after ischaemia and reperfusion, and did so in mitochondrial fractions both containing and lacking connexin 43, so the protection does not run through mitochondrial connexin 43.

PMID: 28369703
Animal2020

Age-related scarring in a conduction-disease model

In Scn5a+/- mice, a model of progressive cardiac conduction disease, the connexin 43 activator Gap-134 prevented the age-related development of ventricular fibrosis, which the authors propose as an anti-fibrotic use.

PMID: 32464326
Animal2020

Recovery after stroke in rats

After focal cerebral ischaemia, synaptic plasticity was reduced by the gap-junction blocker Gap26 and enhanced by GAP-134, evidence that gap junctions take part in recovery and that opening them may aid neurorehabilitation after stroke.

PMID: 32982919
Dosing

No Established Human Dose

Danegaptide has been given to people in two trials, but neither abstract read for this page states an amount: two dose levels alongside primary PCI for heart attack, which did not improve myocardial salvage, and an oral form in diabetic retinopathy, which caused no serious adverse events attributed to it.

What this rests on: PMID 29602883, PMID 42777083.

Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no label and no published test that says what forms or vial sizes Danegaptide is sold in. A vial's own label is a seller's claim, not a source.

Mixing a vial: a worked example

Unknown: no human dose of Danegaptide has been established (see No Established Human Dose below), so there is no amount to work out. The reconstitution calculator does the arithmetic for any vial, water and dose.

Storage before and after mixing

Unknown: no label or published stability study on file says how to store Danegaptide, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Danegaptide stays intact once mixed.

How it is taken

Unknown: with no established human dose, there is no established way of taking Danegaptide. What the human studies gave and how is set out under No Established Human Dose.

What to expect, and when

Unknown: no cited half-life and no label or trial duration on this page says how long Danegaptide lasts or how long it was given. Results reported in the studies are under Published Research.

Side effects, and when to stop or get help

From the Side Effects section: No difference in clinical outcomes from placebo in the 585-patient STEMI trial; No serious drug-related adverse events in the 24-patient retinopathy phase 1b. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping Danegaptide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the trials above”).

Interactions

Unknown: a PubMed search for human interaction studies of Danegaptide (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Danegaptide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Danegaptide's expected mass, 291.3 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: In Clinical Trials (Not approved). Sport: Prohibited (S0 catch-all).

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the trials above.

● No difference in clinical outcomes from placebo in the 585-patient STEMI trial
● No serious drug-related adverse events in the 24-patient retinopathy phase 1b

Contraindications & Cautions

There is no label.

● Not approved for any use
Questions

Frequently Asked Questions

?What is danegaptide?

An investigational oral dipeptide, related to rotigaptide, that modifies connexin-43 gap junctions, the channels that couple neighbouring heart, brain and other cells.

?Did danegaptide work in heart attacks?

No. It shrank infarcts in pigs, but a phase 2 trial with 585 STEMI patients found no difference in salvaged heart muscle, infarct size, ejection fraction or outcomes.

?Why is it being tested in diabetic retinopathy?

In animals and human retinal cells it tightened the blood-retina barrier and countered VEGF-driven leakage, and it can be taken by mouth instead of injected into the eye. A 24-patient phase 1b found no serious drug-related adverse events; efficacy is untested.

Bibliography

References

  1. [other] PubChem CID 16656685, Danegaptide: formula C14H17N3O4, molecular weight 291.30. Read October 3, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/16656685
  2. [fda] FDA. Drugs@FDA (openFDA): no application on record for danegaptide. Read October 3, 2026.
  3. [registry] ClinicalTrials.gov API v2, read October 3, 2026: NCT01977755 (phase 2 cardioprotection proof-of-concept in STEMI, 591 registered, completed).
  4. [clinical-trial] Engstrøm T, et al. "Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2 randomised clinical trial." Heart, 2018;104(19):1593-1599. PMID: 29602883.
  5. [pubmed] Hudson N, et al. "Preclinical and clinical evaluation of systemic danegaptide for the treatment of nonproliferative diabetic retinopathy." Sci Transl Med, 2026;18(868):eaed8692. PMID: 42777083.
  6. [pubmed] Skyschally A, et al. "The antiarrhythmic dipeptide ZP1609 (danegaptide) when given at reperfusion reduces myocardial infarct size in pigs." Naunyn Schmiedebergs Arch Pharmacol, 2013;386(5):383-91. PMID: 23397587.
  7. [pubmed] Freitas-Andrade M, et al. "Danegaptide Enhances Astrocyte Gap Junctional Coupling and Reduces Ischemic Reperfusion Brain Injury in Mice." Biomolecules, 2020;10(3). PMID: 32110860.
  8. [pubmed] Amdisen C, et al. "Testing Danegaptide Effects on Kidney Function after Ischemia/Reperfusion Injury in a New Porcine Two Week Model." PLoS One, 2016;11(10):e0164109. PMID: 27760220.
  9. [pubmed] Squires PE, et al. "Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney." Int J Mol Sci, 2021;22(6). PMID: 33802083.
  10. [pubmed] Hennan JK, et al. "GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs." J Cardiovasc Pharmacol Ther, 2009;14(3):207-14. PMID: 19721133.
  11. [pubmed] Rossman EI, et al. "The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model." J Pharmacol Exp Ther, 2009;329(3):1127-33. PMID: 19252062.
  12. [pubmed] Laurent G, et al. "Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs." Circ Arrhythm Electrophysiol, 2009;2(2):171-8. PMID: 19808462.
  13. [pubmed] Butera JA, et al. "Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation." J Med Chem, 2009;52(4):908-11. PMID: 19175320.
  14. [pubmed] Boengler K, et al. "The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43." Br J Pharmacol, 2017;174(13):2060-2073. PMID: 28369703.
  15. [pubmed] Patin J, et al. "Gap-134, a Connexin43 activator, prevents age-related development of ventricular fibrosis in Scn5a(+/)(-) mice." Pharmacol Res, 2020;159:104922. PMID: 32464326.
  16. [pubmed] Yang K, et al. "Synaptic Plasticity After Focal Cerebral Ischemia Was Attenuated by Gap26 but Enhanced by GAP-134." Front Neurol, 2020;11:888. PMID: 32982919.
  17. [pubmed] Wang JSH, et al. "Matrix-assisted laser desorption/ionization imaging mass spectrometry of intraperitoneally injected danegaptide (ZP1609) for treatment of stroke-reperfusion injury in mice." Rapid Commun Mass Spectrom, 2018;32(12):951-958. PMID: 29575411.
  18. [pubmed] DeLalio LJ, et al. "ZP1609/danegaptide and mitochondrial connexin hemichannels: a harbinger for peptide drug design." Br J Pharmacol, 2017;174(15):2606-2607. PMID: 28567717.

Sources & Citations

Studies were read from their PubMed records and trial registrations from ClinicalTrials.gov, October 3, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-19